RNAscope® ISH Technology from Advanced Cell Diagnostics is a novel multiplex nucleic acid in situ hybridization platform.
ACD caters over 26,000+ catalog RNA probes, designed and ready to use for most research areas and applications.
RNAscope in situ hybridization technology with its proprietary double Z probe design and reagents enable reliable detection of RNA biomarkers at a single molecule sensitivity and high sensitivity within morphological context for FFPE tissues.
With 40+ issued and pending patents, over 2,800 publications and customers in many diagnostic, pharma and academic fields, RNAscope® technology is primed for adoption by the clinical and companion diagnostic community.
With successful partnership with Leica Biosystems the RNAscope® ISH Technology has been optimized for diagnostic and clinical use.
This webinar will focus on the key Dx applications of RNAscope technology in Anatomical Pathology.
This webinar will cover:
- RNAscope technology
- Overview and background
- Utility of RNAscope technology in anatomic pathology
- Specific Dx applications of RNAscope technology (Albumin, IgK/L, HPV)
SPEAKER
 |
|
Robert Monroe, MD, PhD, FCAP
Chief Medical Officer
Advanced Cell Diagnostics, a Bio-Techne brand
|
|
Dr.
Robert Monroe, Chief Medical Officer of Bio-Techne and Advanced Cell Diagnostics, leads the company’s efforts to develop diagnostic and CDx applications with the RNAscope platform.
In this role, Dr.
Monroe works with pathologists and researchers to identify unmet clinical needs in biomarker testing and subsequently oversees development of RNAscope-based tests for these diagnostic applications.
Dr.
Monroe also serves as the clinical lead in ACD’s CDx partnerships with Leica Biosystems and multiple biopharma companies for the development of CDx assays using RNAscope technology.
Prior to ACD, Dr.
Monroe served as Medical Director and VP Laboratory Operations for Veracyte, a diagnostics company focused on molecular cytology.
Prior to Veracyte, Dr.
Monroe served as Chief Medical Officer of BioImagene (acquired by Roche in 2010), a leading provider of imaging solutions for anatomic pathology, where he headed development of software applications for pathologists, including multiple FDA-cleared algorithms for immunohistochemistry.
Dr.
Monroe holds an MD/PhD from Harvard and is board-certified in cytopathology, anatomic pathology, and clinical pathology.
|
|
